News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Brian I. Rini, MD, Cleveland Clinic

Articles by Brian I. Rini, MD, Cleveland Clinic

Experts on RCC

Renal Cell Carcinoma: Future Evolutions in Care

ByBrian I. Rini, MD, Cleveland Clinic,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie A. Berg, DO

July 24th 2023

Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.

Expert on RCC

Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies

ByBrian I. Rini, MD, Cleveland Clinic,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie A. Berg, DO

July 3rd 2023

Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.

Latest Updated Articles

Renal Cell Carcinoma: Future Evolutions in Care
July 24th 2023
Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
July 3rd 2023

Trending on OncLive

Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma

Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer

ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases

How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable

Neoadjuvant/Adjuvant Pembrolizumab Yields EFS Benefits Regardless of Surgical Outcomes in HNSCC